Skip to content

Martin Williams

3 papers in the library · 20 citations · publishing 1971-2026

Papers

Characterization of Alkaloids in Palatable and Unpalatable Clones of Phalaris arundinacea L1

Crop Science March 1, 1971 Martin Williams, R. F. Barnes, John M. Cassady 20 citations

Reed canarygrass genotypes that differ in palatability to lambs also differ in their alkaloid profiles. Unpalatable clones contained an average of 0.78% crude alkaloids on a dry-matter basis, about three times the 0.26% found in palatable clones. The compound 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) was on average 18 times more abundant in unpalatable clones. Other identified alkaloids included gramine, hordenine, and several tryptamine derivatives. The findings suggest that alkaloid concentration, particularly of 5-MeO-DMT, contributes to the palatability differences previously observed in grazing trials.

Rethinking Therapeutic Strategies for Anorexia Nervosa: Insights From Psychedelic Medicine and Animal Models.

Focus (American Psychiatric Publishing) July 1, 2024 Claire J Foldi, Paul Liknaitzky, Martin Williams et al.

Anorexia nervosa has the highest death rate of any psychiatric illness, but current medications are largely ineffective partly because the neurobiological causes are poorly understood. Renewed research into psychedelic medicine, particularly psilocybin, suggests it may help symptoms related to serotonin signaling and cognitive inflexibility in anorexia nervosa. Clinical trials for treatment-resistant depression show promising results, though methodological biases remain. The first clinical trial of psilocybin in anorexia nervosa patients began in 2019, highlighting the need to understand the underlying neurobiological mechanisms. Animal models, such as the activity-based anorexia rodent model, can provide detailed brain and behavior analysis without the confounds of patient expectancy and bias. The authors argue such studies are crucial for informing clinical applications and identifying which patient subpopulations might benefit most.

Qualitative Research on Psilocybin-Assisted Psychotherapy for the Treatment of Mental Disorders: A Scoping Review

Psychedelic Medicine March 1, 2026 Jennifer Pincombe, Martin Williams, Sean Carruthers et al.

A systematic review of qualitative studies on psilocybin-assisted psychotherapy (PAP) for mental disorders found 13 studies covering depressive disorders, anxiety disorders, trauma- and stressor-related disorders, alcohol-use disorder, obsessive-compulsive disorder, and anorexia nervosa. The studies explored 12 topics from pre- to postintervention experiences, mostly using semi-structured interviews with interpretative phenomenological analysis or thematic analysis. The review identifies opportunities for future research, including covering a broader range of mental disorders, exploring longer-term outcomes, sustainability of effects, postintervention support, adverse experiences, comparing active and control group experiences, and including therapist and significant other perspectives with larger sample sizes.